CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 81.48×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
746.89MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.0950xvs all stocks
52-Week Change
191.20%vs all stocks
Market Capitalization
746.89MUSDvs all stocks (USD)
Enterprise Value
298.25MUSDvs all stocks (USD)
Forward P/E
-8.62xvs Biotechnology peers
Price to Book (MRQ)
3.32xvs Biotechnology peers
Enterprise to EBITDA
-21.23xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-10.44%vs Biotechnology peers
Return on Equity (TTM)
-15.02%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-19.48MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-14.13MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.33MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00CADFY2025 · Sep 30, 2025Operating Income
-13.94MCAD-10.00M · vs all stocks (USD)
Pre-tax Income
-12.23MCADFY2025 · Sep 30, 2025Net Income
-12.23MCADFY2025 · Sep 30, 2025EBIT
-13.94MCADFY2025 · Sep 30, 2025EBITDA (Income Statement)
-14.05MCADFY2025 · Sep 30, 2025Research & Development
11.08MCADFY2025 · Sep 30, 2025Selling, General & Administrative
2.57MCADFY2025 · Sep 30, 2025Other Operating Expenses
287.65KCADFY2025 · Sep 30, 2025Non-operating Interest Income
1.52MCADFY2025 · Sep 30, 2025EPS (Basic)
-1.78CADFY2025 · Sep 30, 2025EPS (Diluted)
-1.78CADFY2025 · Sep 30, 2025Basic Shares Outstanding
6.88MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
6.88MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-12.23MCADFY2025 · Sep 30, 2025Operating Cash Flow
-9.30MCADFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
82.91MCADFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-12.23MCADFY2025 · Sep 30, 2025Depreciation & Amortization
76.87KCADFY2025 · Sep 30, 2025Stock-based Compensation
3.18MCADFY2025 · Sep 30, 2025Other Non-cash Items
35.85KCADFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
-362.85KCADFY2025 · Sep 30, 2025Long-term Debt Payments
-100.15KCADFY2025 · Sep 30, 2025Other Financing Charges
-360.14KCADFY2025 · Sep 30, 2025Net Financing Cash Flow
81.64MCADFY2025 · Sep 30, 2025Shares Outstanding
9.81MSharesUpdated Jul 18, 2026Float Shares
5.13MSharesUpdated Jul 18, 2026Shares Short
952.51KSharesUpdated Jul 18, 2026Short Ratio
2.13daysvs all stocks
Short % of Shares Outstanding
12.60%vs all stocks
% Held by Insiders
12.00%vs all stocks
% Held by Institutions
92.92%vs all stocks
Total Cash (MRQ)
220.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
31.56USDUpdated Jul 18, 2026Total Debt (MRQ)
58.50KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0003xvs Biotechnology peers
Current Ratio (MRQ)
81.48xvs Biotechnology peers
Book Value per Share (MRQ)
22.38USDUpdated Jul 18, 2026Total Assets
84.42MCAD60.56M · vs all stocks (USD)
Total Current Assets
84.31MCADFY2025 · Sep 30, 2025Total Liabilities
2.38MCADFY2025 · Sep 30, 2025Total Non-current Assets
111.97KCADFY2025 · Sep 30, 2025Total Non-current Liabilities
41.25KCADFY2025 · Sep 30, 2025Total Current Liabilities
2.34MCADFY2025 · Sep 30, 2025Cash
82.82MCADFY2025 · Sep 30, 2025Cash Equivalents
86.25KCADFY2025 · Sep 30, 2025Cash & Cash Equivalents
82.91MCADFY2025 · Sep 30, 2025Accounts Payable
1.71MCADFY2025 · Sep 30, 2025Short-term Debt
84.53KCADFY2025 · Sep 30, 2025Long-term Debt
41.25KCADFY2025 · Sep 30, 2025Common Stock (Book)
123.25MCADFY2025 · Sep 30, 2025Retained Earnings
-46.58MCADFY2025 · Sep 30, 2025Total Shareholders' Equity
82.04MCAD58.86M · vs all stocks (USD)
52-Week Low
25.56USDUpdated Jul 18, 202652-Week High
123.75USDUpdated Jul 18, 202652-Week Change
191.20%vs all stocks
Beta
0.0950xvs all stocks
50-Day MA
73.95USDUpdated Jul 18, 2026200-Day MA
74.83USDUpdated Jul 18, 2026Avg 10-Day Volume
287.99KSharesUpdated Jul 18, 2026Avg 30-Day Volume
400.70KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.35USDUpdated Jul 18, 2026Other Income / Expense
188.77KCADFY2025 · Sep 30, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 81.48×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 81.48Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Hengli Hydraulic Co., Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Collective Mining Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Coinbase Global, Inc.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets